Trial · NCT00566488
Parathyroid and Thymus Transplantation in DiGeorge #931
NCT00566488, Phase 1, Completed, Sumitomo Pharma Switzerland GmbH
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Parathyroid and Thymus Transplantation in DiGeorge #931. Trials, record NCT00566488. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00566488
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Parathyroid and Thymus Transplantation in DiGeorge #931
- NCT number
- NCT00566488
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 25 participants, actual
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Conditions
- DiGeorge Syndrome, Hypoparathyroidism, Complete DiGeorge Syndrome
- Interventions
- Thymus/Parathyroid Transplantation
- First posted
- 2007-12-03
- Last updated
- 2022-04-04
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy parameter: use of calcium/calcitriol at 1 year post-transplantation. | 1 year after thymus transplantation | Subjects wtih complete DiGeorge anomaly who have received thymus and parathyroid transplants and survived to one year |
| Secondary | Efficacy parameters: ionized calcium | 10-14 months after thymus transplantation | Ionized calcium (normal values are 1.2 - 1.37 mmol/L) |
| Secondary | Efficacy parameters: CD3 count | 10-14 months after thymus transplantation | CD3 count/mm3 |
| Secondary | Efficacy parameters: CD4 count | 10-14 months after thymus transplantation | CD4 count/mm3 |
| Secondary | Efficacy parameters: CD8 count | 10-14 months after thymus transplantation | CD8 count/mm3 |
| Secondary | Efficacy parameters: naive CD4 count | 10-14 months after thymus transplantation | naive CD4 count/mm3 |
| Secondary | Efficacy parameters: naive CD8 count | 10-14 months after thymus transplantation | naive CD8 count/mm3 |
| Secondary | Efficacy parameters: proliferative response to phytohemagglutinin | approximately 1 year after thymus transplantation (8.9 to 17.8 months after transplantation) | proliferative response to phytohemagglutinin in counts per minute |
| Secondary | Efficacy parameters: proliferative response to tetanus toxoid | approximately 1 year after thymus transplantation (8.9 to 17.8 months after transplantation) | proliferative response to tetanus toxoid in counts per minute |
| Secondary | Efficacy parameters: spectra typing at 1 year post transplantation | approximately 1 year after thymus transplantation (12.1 to 18.0 months after transplantation) | Variability of CD4 T cell receptor beta repertoire as assessed by the Kullback-Leibler divergence (DKL) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants4
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| K12HD043494 | Center for Molecular & Cellular Studies of Ped Disease | REED, ANN M. | DUKE UNIVERSITY | EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT | 2003 to 2017 | NIH RePORTER |
| R01AI047040 | Thymic Transplantation in Complete DiGeorge Syndrome | MARKERT, M. LOUISE | DUKE UNIVERSITY | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | 1999 to 2014 | NIH RePORTER |
| R56AI047040 | Thymic Transplantation in Complete DiGeorge Syndrome | MARKERT, M. LOUISE | DUKE UNIVERSITY | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | 2009 | NIH RePORTER |
| R01AI054843 | Dynamics of TCR Repertoire Following Thymus Transplant | MARKERT, M. LOUISE | DUKE UNIVERSITY | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | 2004 to 2008 | NIH RePORTER |
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00566488
GET https://conductscience.org/api/trials/v1/NCT00566488/registered